SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 06/16/2025 at 22:40, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 06/15/2025 at 17:27, 1 year 2 months ago

Sanofi's Dupixent Surpasses Xolair in Phase 4 Study for Chronic Rhinosinusitis with Asthma

Sanofi Dupixent Phase 4 Study CRSwNP Asthma
PRESS RELEASE

published on 06/15/2025 at 17:22, 1 year 2 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and coexisting asthma, showing superior efficacy across all key endpoints in a phase 4 study presented at EAACI

Dupixent Phase 4 Study Asthma Xolair Chronic Rhinosinusitis
BRIEF

published on 06/09/2025 at 23:14, 1 year 3 months ago

Sanofi Releases May 2025 Voting Rights and Shares Data

Voting Rights Shares Regulatory Compliance France Sanofi
PRESS RELEASE

published on 06/09/2025 at 23:09, 1 year 3 months ago

Sanofi: Information concerning the total number of voting rights and shares - May 2025
Sanofi discloses total voting rights and shares information in compliance with French regulations. Details available on Sanofi's investor relations website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 06/09/2025 at 07:05, 1 year 3 months ago

Sanofi prepares early distribution of Beyfortus to counter RSV

Production Sanofi AstraZeneca VRS Beyfortus
PRESS RELEASE

published on 06/09/2025 at 07:00, 1 year 3 months ago

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season, ensuring broad availability and high efficacy for infants

Healthcare Sanofi Vaccine RSV Beyfortus
BRIEF

published on 06/06/2025 at 20:27, 1 year 3 months ago

Sanofi Discloses Repurchase of Own Shares in Early June 2025

Share Repurchase XPAR Market Stock Transaction 2025 Sanofi
PRESS RELEASE

published on 06/06/2025 at 20:22, 1 year 3 months ago

Sanofi: Disclosure of trading in own shares
Sanofi discloses its trading in own shares from 02 June 2025 to 06 June 2025, repurchasing a total of 105,316 shares at an average price of 86.91 EUR per share on XPAR market

Trading Own Shares XPAR Repurchases Sanofi
BRIEF

published on 06/02/2025 at 07:05, 1 year 3 months ago

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

Rare Diseases Sanofi Acquisition Blueprint Medicines Immunology Pipeline Systemic Mastocytosis

Published on 09/11/2026 at 17:00, 1 hour 38 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 15:25, 3 hours 13 minutes ago

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 3 hours 38 minutes ago

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 4 hours 8 minutes ago

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 13:58, 4 hours 40 minutes ago

BlackBerry Radar Advances Asset Intelligence for Transportation

View all ACCESSWIRE

Published on 09/11/2026 at 18:15, 22 minutes ago

CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:07, 31 minutes ago

Holding(s) in Company
Published on 09/11/2026 at 18:06, 31 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 09/11/2026 at 17:30, 1 hour 7 minutes ago

NAGRAVISION and Plume Strengthen Connected Home Security for 30 Million Subscribers Worldwide
Published on 09/11/2026 at 17:30, 1 hour 8 minutes ago

Cairn Homes Plc: Holding(s) in Company

View all EQS

Published on 09/11/2026 at 07:00, 11 hours 38 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 11 hours 38 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 23 hours 8 minutes ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 1 day 11 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 1 day 23 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News